{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:21:01Z","timestamp":1740122461289,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,2,9]],"date-time":"2019-02-09T00:00:00Z","timestamp":1549670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s11239-019-01811-2","type":"journal-article","created":{"date-parts":[[2019,2,9]],"date-time":"2019-02-09T00:32:01Z","timestamp":1549672321000},"page":"427-435","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Guided de-escalation of DAPT in acute coronary syndrome patients undergoing percutaneous coronary intervention with BVS implantation: a post-hoc analysis from the randomized TROPICAL-ACS trial"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0477-2094","authenticated-orcid":false,"given":"Lukasz","family":"Koltowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariusz","family":"Tomaniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Gross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bartosz","family":"Rymuza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Kowara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radoslaw","family":"Parma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Komosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariusz","family":"Klopotowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudius","family":"Jacobshagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso","family":"Gori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Aradi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt","family":"Huber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Hadamitzky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Massberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Lesiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof J.","family":"Filipiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Witkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Opolski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zenon","family":"Huczek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Sibbing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,9]]},"reference":[{"key":"1811_CR1","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1160\/TH16-07-0557","volume":"117","author":"D Sibbing","year":"2016","unstructured":"Sibbing D, Aradi D, Jacobshagen C et al (2016) A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Thromb Haemost 117:188\u2013195. \n                    https:\/\/doi.org\/10.1160\/TH16-07-0557","journal-title":"Thromb Haemost"},{"key":"1811_CR2","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","volume":"390","author":"D Sibbing","year":"2017","unstructured":"Sibbing D, Aradi D, Jacobshagen C et al (2017) Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet 390:1747\u20131757. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(17)32155-4","journal-title":"Lancet"},{"key":"1811_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy332","author":"D Sibbing","year":"2018","unstructured":"Sibbing D, Gross L, Rieber J et al (2018) Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial. Eur Heart J. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehy332","journal-title":"Eur Heart J"},{"key":"1811_CR4","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1016\/j.jacc.2008.04.002","volume":"51","author":"EM Antman","year":"2008","unstructured":"Antman EM, Wiviott SD, Murphy SA et al (2008) Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 51:2028\u20132033. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2008.04.002","journal-title":"J Am Coll Cardiol"},{"key":"1811_CR5","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1093\/eurheartj\/ehr422","volume":"32","author":"RC Becker","year":"2011","unstructured":"Becker RC, Bassand J-P, Budaj A et al (2011) Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 32:2933\u20132944. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehr422","journal-title":"Eur Heart J"},{"key":"1811_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1136\/heartjnl-2015-308963","volume":"102","author":"MA Velders","year":"2016","unstructured":"Velders MA, Abtan J, Angiolillo DJ et al (2016) Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. Heart 102:617\u2013625. \n                    https:\/\/doi.org\/10.1136\/heartjnl-2015-308963","journal-title":"Heart"},{"key":"1811_CR7","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1016\/S0140-6736(16)32050-5","volume":"388","author":"PW Serruys","year":"2016","unstructured":"Serruys PW, Chevalier B, Sotomi Y et al (2016) Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet 388:2479\u20132491. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(16)32050-5","journal-title":"Lancet"},{"key":"1811_CR8","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.4244\/EIJY14M07_11","volume":"10","author":"D Capodanno","year":"2015","unstructured":"Capodanno D, Gori T, Nef H et al (2015) Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention 10:1144\u20131153. \n                    https:\/\/doi.org\/10.4244\/EIJY14M07_11","journal-title":"EuroIntervention"},{"key":"1811_CR9","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1161\/CIRCULATIONAHA.117.031843","volume":"137","author":"ZA Ali","year":"2018","unstructured":"Ali ZA, Gao R, Kimura T et al (2018) Three-year outcomes with the absorb bioresorbable scaffold: individual-patient-data meta-analysis from the ABSORB randomized trials. Circulation 137:464\u2013479. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.031843","journal-title":"Circulation"},{"key":"1811_CR10","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.4244\/EIJ-D-17-00492","volume":"13","author":"S Cassese","year":"2018","unstructured":"Cassese S, Byrne RA, J\u00fcni P et al (2018) Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials. EuroIntervention 13:1565\u20131573. \n                    https:\/\/doi.org\/10.4244\/EIJ-D-17-00492","journal-title":"EuroIntervention"},{"key":"1811_CR11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/09537104.2016.1184750","volume":"27","author":"A Tello-Montoliu","year":"2016","unstructured":"Tello-Montoliu A, Rivera J, Hern\u00e1ndez-Romero D et al (2016) Platelet reactivity over time in coronary artery disease patients treated with a bioabsorbable everolimus-eluting scaffold. Platelets 27:777\u2013783. \n                    https:\/\/doi.org\/10.1080\/09537104.2016.1184750","journal-title":"Platelets"},{"key":"1811_CR12","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/j.jcin.2017.06.067","volume":"10","author":"SG Ellis","year":"2017","unstructured":"Ellis SG, Steffenino G, Kereiakes DJ et al (2017) Clinical, angiographic, and procedural correlates of acute, subacute, and late absorb scaffold thrombosis. JACC Cardiovasc Interv 10:1809\u20131815. \n                    https:\/\/doi.org\/10.1016\/j.jcin.2017.06.067","journal-title":"JACC Cardiovasc Interv"},{"key":"1811_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA et al (2018) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 39:213\u2013260. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehx419","journal-title":"Eur Heart J"},{"key":"1811_CR14","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1093\/eurheartj\/ehy394","volume":"34","author":"F-J Neumann","year":"2018","unstructured":"Neumann F-J, Ahlsson A, Alfonso F et al (2018) 2018 ESC\/EACTS Guidelines on myocardial revascularization. Eur Heart J 34:2949. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehy394","journal-title":"Eur Heart J"},{"key":"1811_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4244\/EIJV14I1A2","volume":"14","author":"T Cuisset","year":"2018","unstructured":"Cuisset T, Capodanno D (2018) Trials of antithrombotic therapy in percutaneous coronary intervention: what evidence do we need to optimise our practice? EuroIntervention 14:19\u201323. \n                    https:\/\/doi.org\/10.4244\/EIJV14I1A2","journal-title":"EuroIntervention"},{"key":"1811_CR16","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0140-6736(15)00979-4","volume":"387","author":"S Cassese","year":"2016","unstructured":"Cassese S, Byrne RA, Ndrepepa G et al (2016) Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. Lancet 387:537\u2013544. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(15)00979-4","journal-title":"Lancet"},{"key":"1811_CR17","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","volume":"36","author":"D Aradi","year":"2015","unstructured":"Aradi D, Kirtane A, Bonello L et al (2015) Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 36:1762\u20131771. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehv104","journal-title":"Eur Heart J"},{"key":"1811_CR18","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/S0140-6736(08)60415-8","volume":"371","author":"JA Ormiston","year":"2008","unstructured":"Ormiston JA, Serruys PW, Regar E et al (2008) A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 371:899\u2013907. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(08)60415-8","journal-title":"Lancet"},{"key":"1811_CR19","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1161\/CIRCULATIONAHA.109.921528","volume":"122","author":"Y Onuma","year":"2010","unstructured":"Onuma Y, Serruys PW, Perkins LEL et al (2010) Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial. Circulation 122:2288\u20132300. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.921528","journal-title":"Circulation"},{"key":"1811_CR20","doi-asserted-by":"publisher","first-page":"734","DOI":"10.4244\/EIJ-D-17-00499","volume":"13","author":"Y Katagiri","year":"2017","unstructured":"Katagiri Y, Stone GW, Onuma Y, Serruys PW (2017) State of the art: the inception, advent and future of fully bioresorbable scaffolds. EuroIntervention 13:734\u2013750. \n                    https:\/\/doi.org\/10.4244\/EIJ-D-17-00499","journal-title":"EuroIntervention"},{"key":"1811_CR21","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1093\/eurheartj\/ehw196","volume":"37","author":"M Haude","year":"2016","unstructured":"Haude M, Ince H, Abizaid A et al (2016) Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial. Eur Heart J 37:2701\u20132709. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehw196","journal-title":"Eur Heart J"},{"key":"1811_CR22","volume-title":"The FANTOM II study: first report for the 12-month clinical outcomes of the Fantom sirolimus eluting bioresorbable scaffold.","author":"A Abizaid","year":"2017","unstructured":"Abizaid A (2017) The FANTOM II study: first report for the 12-month clinical outcomes of the Fantom sirolimus eluting bioresorbable scaffold. EuroPCR, Sao Paulo"},{"key":"1811_CR23","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jcin.2015.12.004","volume":"9","author":"A Abizaid","year":"2016","unstructured":"Abizaid A, Costa RA, Schofer J et al (2016) Serial multimodality imaging and 2-year clinical outcomes of the novel DESolve novolimus-eluting bioresorbable coronary scaffold system for the treatment of single de novo coronary lesions. JACC Cardiovasc Interv 9:565\u2013574. \n                    https:\/\/doi.org\/10.1016\/j.jcin.2015.12.004","journal-title":"JACC Cardiovasc Interv"},{"key":"1811_CR24","doi-asserted-by":"publisher","first-page":"432","DOI":"10.4244\/EIJ-D-17-00254","volume":"13","author":"M Haude","year":"2017","unstructured":"Haude M, Ince H, Kische S et al (2017) Sustained safety and clinical performance of a drug-eluting absorbable metal scaffold up to 24 months: pooled outcomes of BIOSOLVE-II and BIOSOLVE-III. EuroIntervention 13:432\u2013439. \n                    https:\/\/doi.org\/10.4244\/EIJ-D-17-00254","journal-title":"EuroIntervention"},{"key":"1811_CR25","doi-asserted-by":"publisher","first-page":"3070","DOI":"10.1093\/eurheartj\/ehx175","volume":"38","author":"T Cuisset","year":"2017","unstructured":"Cuisset T, Deharo P, Quilici J et al (2017) Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J 38:3070\u20133078. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehx175","journal-title":"Eur Heart J"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-019-01811-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-019-01811-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-019-01811-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,8]],"date-time":"2020-02-08T19:09:13Z","timestamp":1581188953000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-019-01811-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,9]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["1811"],"URL":"https:\/\/doi.org\/10.1007\/s11239-019-01811-2","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"type":"print","value":"0929-5305"},{"type":"electronic","value":"1573-742X"}],"subject":[],"published":{"date-parts":[[2019,2,9]]},"assertion":[{"value":"9 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Lukasz Koltowski received institutional research Grants from Reva Medical Inc., personal fees from Abbott, Boston Scientific, outside the submitted work. Zenon Huczek received personal fees from Medtronic and Abbott, outside of submitted work. Dirk Sibbing reports grants from Roche Diagnostics and Daiichi Sankyo during the conduct of the study; and personal fees from Bayer AG, Daiichi Sankyo, Sanofi, Roche Diagnostics, Pfizer, and AstraZeneca outside of the submitted work. Krzysztof J. Filipiak reports personal fees from Bayer, Boehringer Ingelheim, Krka, Sanofi, Servier, Pfizer, and AstraZeneca outside of the submitted work. Grzegorz Opolski reports speaking and consulting fees from Abbott, Amgen, AstraZeneca, Bayer, Berlin-Chemie\/Menarini, Boehringer Ingelheim, Novartis, Pfizer, Polpharma, Sanofi-Aventis, Servier outside of the submitted work. Maciej Lesiak has received personal fees from Abbott Vascular, Boston Scientific, Biotronik, Terumo and AstraZeneca, outside of submitted work. Kurt Huber reports lecture fees from AstraZeneca, Bayer, Daiichi Sankyo, Pfizer and Sanofi outside of the submitted work. All authors declare that they do not have any further neither financial nor personal relationships with other people or organizations that could inappropriately influence (bias) the research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}